US2010076084A1PendingUtilityA1

Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes

Assignee: GATLIN MARJORIE REGANPriority: Sep 17, 1999Filed: Nov 24, 2009Published: Mar 25, 2010
Est. expirySep 17, 2019(expired)· nominal 20-yr term from priority
A61P 3/10A61K 31/197A61K 31/717A61K 31/64A61K 31/198A61K 9/2054A61P 3/04A61K 31/425A61K 9/2077A61K 31/195A61K 31/44
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

Claims

exact text as granted — not AI-modified
1 - 41 . (canceled) 
   
   
       42 . A method for treating diabetes or preventing the outbreak of diseases and conditions associated with diabetes comprising administering to a patient in need of such treatment or prevention a composition comprising nateglinide or a pharmaceutically acceptable salt thereof, sugar, and microcrystalline cellulose, wherein the sugar and microcrystalline cellulose are present in an amount of from 10-90 to 90-10 percent by weight respectively. 
   
   
       43 . The method according to Claim  42  wherein the diabetes is type 2 diabetes. 
   
   
       44 . A method for decreasing the body weight of a mammal comprising administering to such mammal a composition comprising nateglinide or a pharmaceutically acceptable salt thereof, sugar, and microcrystalline cellulose, wherein the sugar and microcrystalline cellulose are present in an amount of from −90 to 90-10 percent by weight respectively.

Join the waitlist — get patent alerts

Track US2010076084A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.